Perspective Therapeutics (CATX) Selling, General & Administrative (2010 - 2026)
Powered by 
Analysis
Perspective Therapeutics (CATX) Selling, General & Administrative (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 1.75 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 1.92 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 582.20 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 662.10 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -417.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 216.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 347.92 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 709.70 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 165.53 Mn |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - | 7.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.80 Mn |
| Mar 31, 2026 | 6.99 Mn |
| Jun 30, 2025 | 7.71 Mn |
| Mar 31, 2025 | 7.84 Mn |
| Dec 31, 2024 | 8.25 Mn |
| Sep 30, 2024 | 6.98 Mn |
| Jun 30, 2024 | 5.51 Mn |
| Mar 31, 2024 | 5.88 Mn |
| Dec 31, 2023 | 4.94 Mn |
| Sep 30, 2023 | 4.47 Mn |
| Jun 30, 2023 | 4.99 Mn |
| Mar 31, 2023 | 6.66 Mn |
| Dec 31, 2022 | 4.85 Mn |
| Sep 30, 2022 | 6.28 Mn |
| Jun 30, 2022 | 3.16 Mn |
| Mar 31, 2022 | 1.58 Mn |
| Dec 31, 2021 | 1.62 Mn |
| Sep 30, 2021 | 1.84 Mn |
| Jun 30, 2021 | 1.31 Mn |
| Mar 31, 2021 | 1.18 Mn |